Publications by authors named "David M Remick"

Claim this Profile
S
Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile.
Junliang Hao, James Beck, Xin Zhou, Gregory L Lackner, Richard Johnston, David M Remick

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1,3)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor.
Junliang Hao, James P Beck, John M Schaus, Joseph H Krushinski, Qi Chen, David M Remick

J Med Chem· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolation and Physical Property Optimization of an Amorphous Drug Substance Utilizing a High Surface Area Magnesium Aluminometasilicate (Neusilin(®) US2).
Matthew C Allgeier, Jared L Piper, Jeremy Hinds, Matthew H Yates, Kevin J Kolodsick, David M Remick

J Pharm Sci· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.
David M Bender, Jingqi Bao, Anne H Dantzig, William D Diseroad, Kevin L Law, David M Remick

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An investigation into the influence of counterion on the properties of some amorphous organic salts.
Christopher S Towler, Tonglei Li, Håkan Wikström, David M Remick, Manuel V Sanchez-Felix

Mol Pharm· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis